Exome Asset Management LLC — Quarter-over-Quarter 13F Allocation Shifts Q1 2026
In Q1 2026, Exome Asset Management LLC initiated 14 new positions, increased allocation to 4 existing positions, trimmed 10 positions, and exited 22 positions entirely. The fund's 13F equity book declined from $0.20B to $0.17B (-16.1% QoQ) . All deltas are sourced from sequential SEC Form 13F-HR filings; share-count changes reflect explicit trading activity, while weight changes can also include price movement. This page lists every position change reported — the portfolio overview shows a summary of the top shifts.
Net Portfolio Value Change
- $0.20BPrior quarter
- $0.17BCurrent quarter
- $-0.03BNet delta
- -16.1%% change
New Position Initiations Q1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Allocation Weight | History |
|---|---|---|---|
| INSMED INCORPORATED | INSM | 2.56% | Holders → |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 2.36% | Holders → |
| RHYTHM PHARMACEUTICALS, INC. | RYTM | 2.08% | Holders → |
| BOSTON SCIENTIFIC CORP | BSX | 1.79% | Holders → |
| ALKERMES PLC | ALKS | 1.75% | Holders → |
| MONTE ROSA THERAPEUTICS INC | GLUE | 1.74% | Holders → |
| CRESCENT BIOPHARMA INC | CBIO | 1.66% | Holders → |
| RELAY THERAPEUTICS, INC. | RLAY | 1.63% | Holders → |
| MAZE THERAPEUTICS INC | MAZE | 1.55% | Holders → |
| AVALO THERAPEUTICS INC | AVTX | 1.40% | Holders → |
| SOLENO THERAPEUTICS INC | SLNO | 1.21% | Holders → |
| ZENAS BIOPHARMA INC | ZBIO | 0.93% | Holders → |
| 4D MOLECULAR THERAPEUTICS IN | FDMT | 0.72% | Holders → |
| LIPOCINE INC NEW | LPCN | 0.29% | Holders → |
Largest Allocation Increases Q1 2026
Largest portfolio-weight increases in existing positions. Share-count delta is shown separately so price-only re-weighting can be distinguished from active adds.
| Company | Ticker | Δ Weight | Δ Shares | History |
|---|---|---|---|---|
| UNITEDHEALTH GROUP INC | UNH | +1.10% | +120.43% | Holders → |
| CORBUS PHARMACEUTICALS HLDGS | CRBP | +0.73% | +67.79% | Holders → |
| VERASTEM | VSTM | +0.45% | +58.48% | Holders → |
| NOVABRIDGE BIOSCIENCES | NBP | +-0.15% | +15.49% | Holders → |
Largest Allocation Reductions Q1 2026
Largest portfolio-weight decreases in existing positions (positions kept open at a lower allocation).
| Company | Ticker | Δ Weight | Δ Shares | History |
|---|---|---|---|---|
| LIQUIDIA CORPORATION | LQDA | -0.54% | -49.76% | Holders → |
| APELLIS PHARMACEUTICALS INC | APLS | 0.34% | -37.05% | Holders → |
| GLAUKOS CORP | GKOS | -0.43% | -33.67% | Holders → |
| ADAGENE INC | ADAG | 0.71% | -30.50% | Holders → |
| CYTOMX THERAPEUTICS, INC. | CTMX | -0.13% | -30.03% | Holders → |
| NEXTCURE INC | NXTC | -0.44% | -30.00% | Holders → |
| PENUMBRA INC | PEN | -0.17% | -30.00% | Holders → |
| PRAXIS PRECISION MEDICINES I | PRAX | 0.16% | -21.77% | History → |
| PALISADE BIO INC | PALI | -0.26% | -20.87% | Holders → |
| CYTOKINETICS INC | CYTK | 0.11% | -16.86% | History → |
Exited Positions Q1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| WAVE LIFE SCIENCES LTD. | WVE | 3.54% |
| ASTRAZENECA PLC | AZN | 2.60% |
| JAZZ PHARMACEUTICALS PLC | JAZZ | 2.22% |
| IMMUNOVANT, INC. | IMVT | 1.99% |
| UNIVERSAL HLTH SVCS INC | UHS | 1.90% |
| DISC MEDICINE INC | IRON | 1.83% |
| CELCUITY INC | CELC | 1.69% |
| TRAVERE THERAPEUTICS INC | TVTX | 1.68% |
| DEXCOM INC | DXCM | 1.64% |
| IMMUNOCORE HOLDINGS PLC | IMCR | 1.32% |
| EDGEWISE THERAPEUTICS, INC. | EWTX | 1.23% |
| BELITE BIO INC | BLTE | 1.13% |
| WAYSTAR HLDG CORP | WAY | 1.12% |
| IRONWOOD PHARMACEUTICALS INC | IRWD | 1.08% |
| KARYOPHARM THERAPEUTICS INC | KPTI | 1.07% |
| UPSTREAM BIO INC | UPB | 0.87% |
| GOSSAMER BIO INC | GOSS | 0.69% |
| INHIBIKASE THERAPEUTICS INC | IKT | 0.61% |
| IQVIA HLDGS INC | IQV | 0.60% |
| TENET HEALTHCARE CORP | THC | 0.60% |
| FULCRUM THERAPEUTICS INC | FULC | 0.51% |
| RAPT THERAPEUTICS INC | SYN_75382E208 | 0.24% |
Methodology & FAQ
How Exome Asset Management LLC Quarterly Changes Are Computed
Each row above is computed by joining the most recent 13F-HR filing for Exome Asset Management LLC against the immediately preceding quarterly filing for the same fund. Portfolio weights are normalized to exclude listed options for comparability. A complete description of the methodology — including how confidential treatment filings are handled and why share count rather than weight is the cleaner trading signal — is documented in the Methodology.
Which positions did Exome Asset Management LLC initiate in Q1 2026?
Exome Asset Management LLC established 14 new positions in Q1 2026: INSMED INCORPORATED (INSM, 2.56%), MOONLAKE IMMUNOTHERAPEUTICS (MLTX, 2.36%), RHYTHM PHARMACEUTICALS, INC. (RYTM, 2.08%), BOSTON SCIENTIFIC CORP (BSX, 1.79%), ALKERMES PLC (ALKS, 1.75%), MONTE ROSA THERAPEUTICS INC (GLUE, 1.74%), CRESCENT BIOPHARMA INC (CBIO, 1.66%), RELAY THERAPEUTICS, INC. (RLAY, 1.63%), MAZE THERAPEUTICS INC (MAZE, 1.55%), AVALO THERAPEUTICS INC (AVTX, 1.40%), SOLENO THERAPEUTICS INC (SLNO, 1.21%), ZENAS BIOPHARMA INC (ZBIO, 0.93%), 4D MOLECULAR THERAPEUTICS IN (FDMT, 0.72%), LIPOCINE INC NEW (LPCN, 0.29%).
Which existing positions saw the largest allocation increases for Exome Asset Management LLC in Q1 2026?
The largest portfolio-weight increases in existing positions were: UNITEDHEALTH GROUP INC (UNH, +1.10% weight, +120.43% shares), CORBUS PHARMACEUTICALS HLDGS (CRBP, +0.73% weight, +67.79% shares), VERASTEM (VSTM, +0.45% weight, +58.48% shares), NOVABRIDGE BIOSCIENCES (NBP, +-0.15% weight, +15.49% shares).
Which positions did Exome Asset Management LLC fully exit in Q1 2026?
Exome Asset Management LLC fully exited 22 positions in Q1 2026: WAVE LIFE SCIENCES LTD. (WVE, last-reported weight 3.54%), ASTRAZENECA PLC (AZN, last-reported weight 2.60%), JAZZ PHARMACEUTICALS PLC (JAZZ, last-reported weight 2.22%), IMMUNOVANT, INC. (IMVT, last-reported weight 1.99%), UNIVERSAL HLTH SVCS INC (UHS, last-reported weight 1.90%), DISC MEDICINE INC (IRON, last-reported weight 1.83%), CELCUITY INC (CELC, last-reported weight 1.69%), TRAVERE THERAPEUTICS INC (TVTX, last-reported weight 1.68%), DEXCOM INC (DXCM, last-reported weight 1.64%), IMMUNOCORE HOLDINGS PLC (IMCR, last-reported weight 1.32%), EDGEWISE THERAPEUTICS, INC. (EWTX, last-reported weight 1.23%), BELITE BIO INC (BLTE, last-reported weight 1.13%), WAYSTAR HLDG CORP (WAY, last-reported weight 1.12%), IRONWOOD PHARMACEUTICALS INC (IRWD, last-reported weight 1.08%), KARYOPHARM THERAPEUTICS INC (KPTI, last-reported weight 1.07%), UPSTREAM BIO INC (UPB, last-reported weight 0.87%), GOSSAMER BIO INC (GOSS, last-reported weight 0.69%), INHIBIKASE THERAPEUTICS INC (IKT, last-reported weight 0.61%), IQVIA HLDGS INC (IQV, last-reported weight 0.60%), TENET HEALTHCARE CORP (THC, last-reported weight 0.60%), FULCRUM THERAPEUTICS INC (FULC, last-reported weight 0.51%), RAPT THERAPEUTICS INC (SYN_75382E208, last-reported weight 0.24%).
Which existing positions saw the largest allocation reductions for Exome Asset Management LLC in Q1 2026?
The largest portfolio-weight reductions in positions kept open were: LIQUIDIA CORPORATION (LQDA, -0.54% weight, -49.76% shares), APELLIS PHARMACEUTICALS INC (APLS, 0.34% weight, -37.05% shares), GLAUKOS CORP (GKOS, -0.43% weight, -33.67% shares), ADAGENE INC (ADAG, 0.71% weight, -30.50% shares), CYTOMX THERAPEUTICS, INC. (CTMX, -0.13% weight, -30.03% shares), NEXTCURE INC (NXTC, -0.44% weight, -30.00% shares), PENUMBRA INC (PEN, -0.17% weight, -30.00% shares), PRAXIS PRECISION MEDICINES I (PRAX, 0.16% weight, -21.77% shares), PALISADE BIO INC (PALI, -0.26% weight, -20.87% shares), CYTOKINETICS INC (CYTK, 0.11% weight, -16.86% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity.